Fulcrum Capital LLC Sells 408 Shares of Johnson & Johnson $JNJ

Fulcrum Capital LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 8.2% in the second quarter, HoldingsChannel reports. The fund owned 4,573 shares of the company’s stock after selling 408 shares during the period. Fulcrum Capital LLC’s holdings in Johnson & Johnson were worth $699,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth about $35,000. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth about $48,000. Finally, von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on JNJ. Morgan Stanley upped their price objective on Johnson & Johnson from $176.00 to $178.00 and gave the company an “equal weight” rating in a research note on Friday. Bank of America upped their price objective on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. The Goldman Sachs Group upped their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Finally, Citigroup upped their price objective on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $192.94.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.88 on Tuesday. The company has a market capitalization of $459.71 billion, a PE ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40. The company has a 50 day simple moving average of $178.88 and a two-hundred day simple moving average of $163.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.